The Sequencing Framework for Commercial Technology

From Operate
to Transform

The decision system for what to build next — and in what order

A sequencing model for commercial technology investment — built in pharma, applicable beyond it. Four load-bearing tiers. One non-negotiable order.

SG
Personal Perspective From
Saurav Gupta
Commercial Product, Technology & Strategy · Pharma Industry Practitioner
10–15%
of commercial tech investments measurably move brand KPIs [1]
60%
of AI projects lacking AI-ready data are abandoned before delivering value [1]
2×
revenue growth for highest omnichannel maturity vs. average peers [6]
Billions
in annual pharma SG&A spend — the problem is sequence, not investment [21]
B
Build to Operate
CRM · Hub · Claims · HCP identity · Field workflows
E
Enable
MDM · CDP · Omnichannel · Identity · Consent
A
Accelerate
NBA engine · AI field chat · PA automation · Routing
T
Transform
Agentic PA · Autonomous decisions · AI commercial model
Scroll
B Build the foundation right · E Enable intelligent decisions · A Accelerate commercial outcomes · T Transform the operating model
Why B·E·A·T

The framework pharma commercial
organizations actually need

Not another technology playbook. A sequencing model built from real decisions — on which capabilities to build, in what order, and why skipping any tier creates compounding costs downstream.

For Commercial Technology Leaders
Answer the question every SVP asks
"Are we investing in the right tier — or the tier we wish we were in?" B·E·A·T gives you a structured answer with gates that protect every dollar above them.
Use the Decision Tool →
For AI and Digital Strategy
60% of AI projects lacking AI-ready data will be abandoned before they deliver value. [1] Here is why.
Not because of the AI. Because Enable was skipped. A Next-Best-Action engine deployed on un-mastered HCP identity makes confident wrong recommendations. The sequence is structural.
See AI at Scale →
For Executive Stakeholders
Transform is a state you earn, not announce
Agentic workflows, autonomous PA, self-optimizing omnichannel — all require B, E, and A to be production-stable first. Three real scenarios show exactly how it works in practice.
See Use Cases →
Sequence first
Skip a tier and you don’t fall behind — you pay to rebuild it.
The framework makes the cost of skipping visible before you skip.
Gate everything
Every tier has a gate. The gate is not the calendar. It is the data.
MDM match rate, CRM completion, claims latency — explicit and measurable.
AI is a tier, not a shortcut
60% of AI projects lacking AI-ready data will be abandoned before they deliver value. [1] The foundation was never built to carry them.
The B·E·A·T sequence is what makes agentic AI safe to deploy.
Built from observation
Synthesized from patterns seen across industry launches, migrations, and AI deployments that worked — and many that didn’t.
Industry research grounded. Practitioner-refined. Applicable beyond pharma.
SG
Personal Perspective — Author Disclaimer
The views expressed are those of Saurav Gupta personally and do not represent any employer, client, or affiliated organization. This framework is original practitioner work. © 2026 Saurav Gupta.
01 — The Problem

The technology worked.
The foundation didn’t.

A sequencing problem. Not an investment problem.

Pharma commercial organizations have spent billions on digital over the past five years. The outcomes have been uneven — not because the tools failed, but because the foundation underneath them was never stable enough to carry the weight.

A Next-Best-Action (NBA) engine deployed on un-mastered prescriber data generates recommendations the field can’t act on. A patient access platform built without a live claims feed leaves hub operations flying blind. A generative AI tool writes for HCPs (Healthcare Providers) who changed practice settings eight months ago. In every case, the technology worked. The foundation didn’t. [1, 2, 8]

The problem is not investment. Large pharma companies spend an average of 25–40% of revenue on SG&A — which includes all commercial operations, technology, and field force costs [21]. The problem is not investment. The problem is sequence. Organizations invest in the tier they wish they were in, not the tier they’re actually in. They fund Accelerate without having built stable Enable. They announce Transform without having proven Accelerate. And when it fails, they call it an AI problem. It was always a sequencing problem. [3, 19]

The B·E·A·T Framework
“Skip a step and you don’t just fall behind — you EAT the cost of rebuilding. The sequence is structural. Every tier carries the weight of what sits above it.”
Build Failure
CRM (Customer Relationship Management) data degrades. HCP affiliation accuracy degrades materially without active MDM (Master Data Management) governance. Every AI model above inherits the rot. [6]
Enable Skipped — Field Force Pays the Price
Stale CRM data. No MDM. NBA routes the rep to a practice the physician left two quarters ago. An NBA system that requires mastered identity to achieve its 30–40% engagement lift will produce the opposite on fragmented data. [28] The Reimbursement Specialist gets a case with the wrong payer ID. The Medical Liaison schedules an exchange at the wrong institution. One data failure. Three field roles flying blind. [6, 9]
Accelerate Before Gates
Patient access platform launches without live claims feed. Hub operations blind. Time-to-first-fill degrades. Field loses confidence in platform within 60 days. [7]
Transform Announced Prematurely
Agentic AI deployed before claims feeds reliable, HCP identity mastered. Agent makes confident wrong decisions at commercial scale. Credibility cost outlasts technology cost. [1, 2]
→
Only 10–15% of commercial tech investments measurably move brand KPIs [1] and 60% of AI projects lacking AI-ready data will be abandoned before they deliver value. [1] . The organizations that with the highest omnichannel maturity show 2× the revenue growth of average peers [6]. The difference is not the tool. It is the order.
02 — The Framework

B·E·A·T — Four tiers. One sequence.

Each tier is load-bearing for the next. Build is the floor. Enable is the ceiling on every decision above it. Accelerate is where technology starts moving commercial outcomes. Transform is the model reinvention that only works when the other three are stable.

B · Build · Now & Always
Commercial Operations Floor
The systems and data flows that keep commercial operations running reliably and compliantly. Every investment above depends on this being stable.
CRM · Hub enrollment · Claims feeds · HCP/HCO identity · Reimbursement Specialist workflows · Patient consent · Call planning data
KPI: CRM completion rate · Hub SLA · Claims latency · Reimbursement Specialist case volume · Medical Liaison call quality
If Build is unstable
CRM data degrades materially without active MDM governance — HCP affiliation accuracy erodes silently over months. Every AI model above inherits the rot. NBA routes field teams to wrong practices. Reimbursement Specialist cases file against wrong payer IDs. The foundation rots silently — until the AI announces it loudly. [6, 8]
E · Enable · Intelligence Layer
Decision Quality Ceiling
Raises the ceiling on every downstream decision. Without mastered identity and unified signal, AI recommendations are confidently wrong. [23, 1]
MDM · CDP (Customer Data Platform) · Omnichannel backbone · Consent architecture · Insights infrastructure
KPI: HCP match rate · Channel coherence score · Data freshness index
If Enable is skipped
The same prescriber commonly exists as separate records across multiple commercial systems with no master record. NBA deploys on fragmented identity — generating recommendations the field cannot act on. AI chat briefs reps on physicians who moved practice settings. NBA platform investment written off at 6-month review. [9]
A · Accelerate · Revenue Tier
Commercial Outcomes Engine
Where technology begins directly moving commercial outcomes. PA (Prior Authorization) automation reduces time-to-therapy 42–58%. AI copilots cut field admin 25–30%. AI-driven dynamic targeting routes the right rep, Medical Liaison, or Reimbursement Specialist at the right moment. [13, 14]
NBA (Next-Best-Action) engine · Dynamic targeting & routing · AI field chat · PA automation · Reimbursement Specialist automation · Outcomes Liaison outcomes tracking
KPI: TRx (Total Prescriptions) lift · Time-to-therapy · PA deflection rate · Reimbursement Specialist case resolution · Outcomes Liaison engagement quality
If Accelerate is mis-gated
Transform deployed without proven Accelerate lift. Agentic workflows inherit unvalidated logic. The agent makes autonomous decisions on a process that was never proven to work at scale. PA automation fires without live claims feeds. Credibility cost outlasts technology cost by years. [1, 2]
T · Transform · Model Shift
Operating Model Reinvention
Not process efficiency — commercial model reinvention. Agentic workflows, autonomous PA, self-optimizing omnichannel. Only works when B·E·A are production-stable. [2, 18]
Agentic PA · Dynamic territory AI · Autonomous formulary response · Self-optimizing omnichannel · AI commercial model
KPI: Decisions automated · Cost per patient · Hub case deflection rate
If Transform is announced before B·E·A are earned
Board approves agentic AI roadmap for Year 1. Build not stable. Enable not mastered. Agent deploys into an environment it can’t trust. It fires on ghost approvals. MLR (Medical, Legal, Regulatory) review finds no audit trail. Program suspended indefinitely. [15]
Without Sequence

The technology
worked. The
foundation didn’t.

✗ Without B·E·A·T Sequence
NBA deployed on 14-month-old HCP data. Targeting accuracy compromised from day one.
Same prescriber exists across multiple disconnected systems. AI recommendations built on fragmented identity are confidently wrong.
PA automation fires without live claims feed. Time-to-first-fill remains above 18 days. Siloed hub systems mean Reimbursement Specialists lack visibility into patient journey data. [13, 33]
Rep, Medical Liaison, Reimbursement Specialist, and Outcomes Liaison working from four separate systems. No shared account view.
Agentic AI deployed. Claims feed unreliable. Agent fires on ghost approvals.
Leadership calls it an AI problem. It was always a sequencing problem.
With Sequence

The sequence
is structural.
Every tier loads the next.

✓ With B·E·A·T Sequence
NBA gated on MDM match rate ≥82%. Rep targeting grounded in clean, mastered HCP identity. [15]
Single mastered prescriber identity. AI recommendations grounded in clean signal.
PA automation on live claims. Time-to-first-fill drops from an 18-day average to under 10 days. [13]
AI dynamic routing sends the right person to the right account. One shared view.
Agentic PA on production-stable B·E·A. PA processing time compressed materially with automation. [16, 18]
Organizations with the highest omnichannel maturity show 2× the revenue growth of average omnichannel maturity peers [6].
“The difference is not the technology. It is the order in which it is built.”
03 — How to Prioritize

Score your B·E·A·T — then BET on the right sequence

Know where you EAT risk  ·  and where you AT scale

Criterion
Score 1
Score 3
Org scale
Portfolio breadth and resourcing capacity
Small
Large
Speed pressure
Launch window or competitive urgency
Urgent
Low
Tech maturity
CRM, claims, MDM stability today
Low
High
Capital runway
Budget and brand lifecycle stage
Tight
Full
Change capacity
Field and ops adoption bandwidth
Low
High
Compliance burden
GxP, HIPAA, MLR cycle speed
Heavy
Light
6–9
Sequential only. Build stabilizes before Enable begins.
10–13
Selective parallel. B+E only. Accelerate after gates.
14–17
Aggressive parallel. Accelerate early. Transform scoped.
18
All tiers concurrent. Transform pilotable now.
Investment Posture Matrix — Technology Maturity × Time-to-Market Pressure [3, 5]
Q1 · Build Deep
All tiers, Transform focus
Stable B+E. Low urgency. Invest deliberately across all tiers through Transform.
B
E
A
T
14–18
Q2 · Accelerate Now
Parallel B+E, fast A
Urgency demands Accelerate in 6 months. Transform scoped for Year 2.
B
E
A
T
11–16
Q3 · Build Sequentially
B first, E next
Low maturity forces strict sequence. A & T are future state. No skipping.
B
E
A
T
6–10
Q4 · Triage & Compress
MVP B + wrapper E
No time for perfect B. Accept higher risk. Transform deferred until post-launch.
B
E
A
T
6–10
↑ High MaturityHigh Urgency →
↺
The sequence never changes. Only the pacing does. BET on the wrong order and you EAT the cost of rebuilding. Every org — Quadrant 1 or Quadrant 4 — must Build before it Enables, Enable before it Accelerates, and Accelerate before it Transforms. [3, 19]
04 — The Customers You’re Building For

Four stakeholders. Four gaps.
One sequence closes all of them.

Click Today / 2030 on each card to toggle between the current state and the future state that B·E·A·T enables. [5, 6]

HCPSpecialist · High-volume prescriber
From fragmented noise → to one coherent signal
4–6 rep visits/week with duplicated information. Three reps from the same company present conflicting formulary data in the same month. Digital sends emails she didn’t opt into. [11]
One signal across every channel — unified HCP and patient profiles connecting sales, medical, and patient support. The rep arrives knowing her patient panel, current formulary, and what she asked about last time. Non-relevant outreach has stopped. [17, 30]
E MDM → A NBA → T Omnichannel coherence
PatientSpecialty · Hub enrollment
From 18-day wait → to access that resolves itself [13]
Approved for a biologic Tuesday. Calls hub four days later, told to call back. Prior authorization pending 18 days on average without technology-enabled automation. An estimated 3 out of 4 specialty brand patients fail to fill a new prescription due to payer controls. [20] [13] PA delays range from days to weeks without hub integration; e-enrollment reduces time to therapy by up to 4 days. [33] First fill never happens. Over 90% of physicians report patient care delays due to prior authorization complexity — the primary barrier in specialty access. [17] [5, 7]
With PA automation: high-risk authorizations reduce from 8–10 days to 24–48 hours, with full automation enabling near-real-time adjudication. [16, 22] Bridge program activated before the patient asks. Time-to-first-fill under 8 days. No form. No phone call. [13, 15]
B Hub ops → E Claims CDP → A PA automation → T Agentic
Field TeamRep · Medical Liaison · Reimbursement Specialist · Outcomes Liaison
From siloed roles, fragmented data → to one coordinated signal
The rep, Medical Liaison, Reimbursement Specialist, and Outcomes Liaison each work from different systems with no shared account view. The rep calls on the prescriber Tuesday. The Medical Liaison schedules a scientific exchange Thursday — neither knows the other was there. [6, 14]
AI-driven dynamic targeting routes the right person — rep, Medical Liaison, Reimbursement Specialist, or Outcomes Liaison — to the right account based on current signal. An AI chat interface surfaces account context at point of call. All from one mastered HCP/HCO identity. PA processing time reduced 30%+ with AI automation. [16]
B CRM/Field mgmt → E MDM + HCO hierarchy → A Dynamic routing + AI chat → T Coordinated field AI
PayerPharmacy director · IDN · PBM
From quarterly lag → to real-time outcomes intelligence
Formulary proposals arrive without real-world outcomes data she can verify. The Reimbursement Specialist calls quarterly with pull-through reports the payer can’t reconcile. Coverage change decisions happen without manufacturer awareness — the field finds out from a rejected PA. [5, 10]
Real-time formulary pull-through mapped to her own claims. The Reimbursement Specialist arrives with verified outcomes data. Coverage changes trigger manufacturer alerts within hours. Predictive contract modelling shows both sides the outcome before negotiation begins. [19, 8]
B Payer master + claims → E Payer analytics → A Reimbursement Specialist + Outcomes Liaison intelligence → T Autonomous formulary
05 — Use Cases

B·E·A·T in practice

Three real pharma commercial scenarios. Each shows exactly how sequencing applies — and what breaks when a tier is skipped.

01
Specialty Brand Launch — Year 1 Go-Live
Pre-launch greenfield · Specialty / complex therapy · Quadrant 4 (Triage & Compress) · Score: 7
B active E compress Urgent · Low maturity
EXECUTIVE TAKEAWAY
Ship Build first, even if it delays launch by weeks. Industry evidence shows that fragmented commercial data at launch leads to slower script uptake and field credibility loss — consequences that outlast the delay. [24]
► THE SITUATION Launch in 12 months. CRM last refreshed 18 months ago. Hub onboarding manual — averaging 18 days without automation [13]. No MDM. NBA vendor already contracted. Leadership wants AI copilot at launch. Industry evidence shows 89% of biopharma AI pilots fail to scale, with data fragmentation as the primary cause. [24]
THE B·E·A·T SEQUENCE
B
BUILD
M1–M4
Emergency CRM refresh. NPI hierarchy corrected. Hub workflow digitized. Claims feed connected. Data quality baseline established before any AI investment.
Gate: CRM completion ≥90%
96% of pharma leaders say data is not AI-ready for scaling pilots. Build solves this first. [24]
E
ENABLE
M3–M7
MVP MDM layer. Single prescriber identity. CDP ingesting enrollment and claims. Consent architecture production-grade.
Gate: MDM match rate ≥82%
73% of leaders report significant HCP data quality issues. MDM resolves the root cause. Organizations that unify data sources unlock downstream AI — unified profiles enable next best action and personalized engagement. [24, 31]
A
ACCELERATE
M8 (launch)
NBA go-live gated on MDM match rate — NOT the launch date. AI copilot activated. PA automation live on clean claims feed. Dynamic HCP targeting active.
Gate: match rate, not calendar
Organizations with strong data foundations see measurable sales uplift vs. those that deploy on fragmented data. AI-enabled NBA improves HCP engagement by 30–40% when built on mastered identity. [24, 5, 28, 29]
T
TRANSFORM
Year 2+ (scoped)
Agentic PA piloted after Accelerate proves stable at scale. Score of 7 does not support Transform now.
Deferred explicitly
Scaling AI without B·E stable is the most common failure mode in commercial pharma. The technology is rarely the limiting factor; data and process architecture is. [24, 26, 34]
▶ WHAT BREAKS IF A DEPLOYS BEFORE E REACHES ≥85%?
NBA launches on stale HCP data. Field receives recommendations they cannot act on. Trust erodes within weeks. [24]
AI copilot briefs reps on HCPs who moved practice settings. Credibility cost outlasts technology cost. [1, 2]
PA automation fires without live claims feed. Time-to-first-fill remains above 18 days. Siloed hub systems mean Reimbursement Specialists lack visibility into patient journey data. [13, 33]
NBA platform investment written off. Leadership calls it an AI problem. It was always a sequencing problem. Industry AI projects fail not because of models — but because of data fragmentation and sequencing gaps. [24, 25, 34]
RESULT
9 days
Time-to-first-fill
from 18-day avg [13]
15%+
Higher early script volume
vs. fragmented launch [24]
2 mo.
Launch delay avoided
by sequencing correctly [24]
NBA deploys 4 weeks post-launch (not at launch). Time-to-first-fill drops from an 18-day historical average to under 10 days. [13] Field teams trust recommendations because data quality was established first — the foundation that 96% of pharma leaders say is missing. [Ref. 3, 13, 24]
02
Mature Multi-Brand Portfolio — CRM Consolidation & MDM Build
3 legacy CRMs from acquisitions · Low urgency · Quadrant 1 (Build Deep) · Score: 15
All tiers active Parallel B+E Low urgency · High maturity
EXECUTIVE TAKEAWAY
High maturity earns parallel tracks. But E still gates A. The MDM match rate is the difference between AI that works and AI that routes confidently wrong. A unified HCP identity is what makes every downstream model trustworthy. [23, 24]
► THE SITUATION Three legacy CRM systems from three acquisitions. No single HCP identity. MDM project stalled 2 years. 72% of companies spend up to 100 days annually reconciling HCP data across sources — a pattern directly documented across pharma commercial technology implementations. [24] Leadership wants AI-driven territory optimization by Q3.
THE B·E·A·T SEQUENCE
B
BUILD
Stream 1 · M1–M6
CRM consolidation. Single rep activity record. Claims normalized. Parallel track — does not wait for E.
Parallel with Enable
E
ENABLE
Stream 2 · M1–M8
MDM build. Single prescriber master. CDP integrates CRM, claims, and digital. Consent architecture embedded.
Gate: ≥85% match rate
A
ACCELERATE
M9–M14
NBA + AI dynamic targeting routes rep, Medical Liaison, and Reimbursement Specialist by signal. AI chat at point of call. Omnichannel NBA drives 15–40% increase in HCP engagement when built on mastered identity. Data-driven targeting significantly improves field effectiveness and engagement outcomes. [16, 28, 29]
Unlocks after E gate
T
TRANSFORM
Year 2
Dynamic territory reallocation by AI in-week. Reimbursement Specialist cases auto-routed. Outcomes Liaison outcomes mapped to payer cohorts in real time.
After A proves lift
▶ WHAT BREAKS IF A DEPLOYS BEFORE E REACHES ≥85%?
NBA deploys on fragmented identity. AI routes based on the loudest data source, not the correct one. [23, 24]
Rep targeting wrong for 1 in 3 accounts. Medical Liaison and Reimbursement Specialist still scheduling from separate systems.
Q3 territory optimization request becomes a credibility crisis. Field disengages from AI tooling. MDM loses executive sponsorship. [25, 26, 34]
RESULT
~50%
Duplicate HCP records eliminated
after MDM consolidation [23]
30%
Improvement in field call prioritization accuracy
with AI/predictive models [23]
Improved
AI chat adoption
as data quality improves [8]
B+E parallel tracks merge at Month 8. Mastered identity is what makes routing trustworthy. Consolidating legacy CRMs into a single engagement graph reduced duplicate HCP records by nearly half and improved launch readiness by 25%+ in one documented global program. [Ref. 3, 14, 23]
03
Large Pharma — Agentic Patient Services at Scale
All tiers operational · Full Transform ambition · Quadrant 1 · Score: 17
Transform active Low urgency · High maturity
EXECUTIVE TAKEAWAY
Transform is not a destination you announce. It is a state you earn — tier by tier. The agentic PA program works because every upstream dependency was already production-stable. Without that foundation, automation at scale is the fastest way to destroy field trust. [24, 26]
► THE SITUATION B and E are stable. NBA is live on a mastered HCP identity layer. PA automation is reducing processing time by 30%+ vs. manual workflows. [16] Board has approved agentic patient services: autonomous PA drafting, submission, and appeal — enabled by production-stable Build and Enable tiers. Only 11% of companies reach this level of value realization. [25]
THE B·E·A·T SEQUENCE
B
BUILD
Stable · gates passed
CRM complete. Claims feed live. Hub enrollment documented SLA. HCP hierarchy ≥92% accuracy. PA and benefit verification require integrated claims visibility before any automation layer is added. [33, 32]
✓ Gates passed
E
ENABLE
Stable · gates passed
Unified identity live. Consent architecture production-grade. Closed-loop signal returning outcomes. MLR-auditable data lineage embedded.
✓ Gates passed
A
ACCELERATE
Active · optimizing
NBA live on mastered identity. PA automation reducing processing time 30%+ vs. manual. [16] EY documents that end-to-end PA digitization requires integrated claims data and unified patient identity as the foundation. [32] Closed-loop signal feeds back to models weekly. [Ref. 3, 14, 15]
✓ Lift proven
T
TRANSFORM
Year 2
Agentic PA: autonomous drafting, submission, appeal, routes to hub — no human initiates. MLR-embedded reasoning. Compliance audit trail native to every agent action. Agentic AI requires production-stable foundations; automation amplifies errors at scale when data architecture is not ready. [34]
Earned — piloting now
▶ WHAT IF TRANSFORM LAUNCHED BEFORE A WAS PROVEN?
Agent inherits unvalidated workflow logic. Confident wrong decisions at commercial scale. [24, 1]
Claims feed not production-grade. Agent fires on stale approvals. Patients receive submissions for plans that already denied.
MLR has no audit trail for agent reasoning. First denied appeal triggers regulatory review. Program suspended indefinitely. Agentic AI without data maturity amplifies errors at commercial scale rather than reducing them. [1, 2, 34]
Board withdraws agentic AI investment across all programs — not just patient services. Credibility cost outlasts technology cost by years. 70% of digital transformations that skip sequencing fail to achieve their objectives; only 30% of transformations succeed in achieving their objectives and creating sustainable change. [26, 27]
RESULT
<48h
PA processing
with automation [16]
Growing%
Hub case automation
on stable B·E·A foundation [18]
0
PA cases by field rep
fully autonomous
Only possible because B·E·A were earned first. Every tier below this one was load-bearing. The 11% of companies that reach scaled AI value share this pattern: they built the foundation before deploying the intelligence. EY confirms that PA automation at scale requires end-to-end integration and a digital operating model — not just technology. [Ref. 15, 18, 25, 32]
06 — AI at Scale

Enabling B·E·A·T for AI-first commercial delivery

Don’t skip a BEAT  ·  EAT the data problem first  ·  AT the frontier only when earned

The gap the four stakeholders revealed
Every stakeholder on the Customers page has a 2030 expectation that requires AI to deliver it. The HCP’s coherent signal requires a mastered identity layer. The patient’s self-resolving access journey requires agentic PA. The field team’s AI-briefed calls require a closed-loop signal. The payer’s real-time intelligence requires autonomous formulary response. None of these are AI problems. They are all sequencing problems. The organizations that reach these outcomes will have earned them — tier by tier. [3, 4, 19, 27]
LAYER ↓
SEQUENCE →
B
E
Don’t skip a Beat
Foundational
E
A
T
EAT the data problem
Intelligence
A
T
AT the frontier
Transformation
INFRA &
DATA
Modular, API-first design
Monolithic platforms create sequencing debt. Each capability — CRM, hub, claims, MDM, NBA — must be independently upgradeable. Build this from day one or pay to rebuild at every tier transition. [19]
Unified Commercial Identity
The AI-first model breaks wherever the same person has a different identity in different systems. A single, persistent, consent-aware identity across CRM, hub, claims, digital, and medical is the prerequisite for everything above it. The same HCP commonly exists as separate records across CRM, hub, claims, digital, and medical affairs systems — without a single mastered identity. [9]
Closed-Loop Signal Architecture
AI models degrade silently without outcome feedback. Connect every commercial action back to a measurable result in near real time. Without this loop, models become confidently wrong over time. [11, 12]
INTEL &
DECISIONS
AI-Ready Data Governance
Tag every data asset with lineage, consent state, freshness, and confidence at ingestion. The question at every Build and Enable investment: can an AI model consume this autonomously? [8, 10]
Build the Environment, Then the Agent
Live claims feeds, mastered identity, and compliant consent records are not prerequisites for the agent — they are the agent’s operating environment. B·E·A must be production-stable before T can act with confidence. [1, 2]
Governance Embedded in Compliance Review
Pharma’s Transform tier operates under a compliance ceiling that doesn’t exist elsewhere. AI decisions require auditable reasoning for regulatory review. Governance built from Enable forward is the difference between Transform that scales and Transform that stalls at legal. [16, 8]
Build · Now
Every data asset tagged for AI consumption. API-first design from first commit. No MDM = no AI budget approved. [6, 8]
Enable · M3–M8
Unified identity live. Consent architecture production-grade. A unified HCP data platform connects CRM, claims, and engagement history — the prerequisite for trusted AI recommendations. [9, 10, 31]
Accelerate · M8–M18
NBA live on mastered identity. PA automation reducing processing time 30%+. [16] Models retraining on live signal. [12, 13, 14]
Transform · Year 2–3
Agentic PA. Autonomous formulary response. Self-optimizing omnichannel. Agentic automation of commercial workflows accelerates as B·E·A foundations mature. [2, 18]
07 — The Practitioner Guide

Don’t skip a BEAT — or you’ll AT the wrong tier

This is a gate system, not a checklist. Each gate must be passed before the next tier unlocks. [3, 19]

The Five Practitioner Gates
1
Build gate — Data integrity audit
Before any Enable investment, run a full CRM data quality audit. NPI (National Provider Identifier) hierarchy accuracy must exceed 85%. Claims feed latency must be under 24 hours. Hub enrollment SLA (Service Level Agreement) must be documented. If not met, no Enable investment should be approved. [6, 12]
B is the floor. You don’t lay carpet before you pour concrete.
2
Enable gate — Master data match rate
MDM match rate must reach ≥85% before NBA go-live — not at the launch date, not on the project plan date. The Accelerate tier is gated on Enable quality. This is the most commonly skipped gate in pharma commercial. It is why 60% of AI projects lacking AI-ready data will be abandoned before they deliver value. [1]
EAT the data problem before it eats your AI investment.
3
Accelerate gate — Outcomes before scale
Prove measurable commercial lift before scaling any Accelerate investment. NBA must show attributable TRx (Total Prescriptions) lift in a pilot cohort before fleet-wide deployment. PA automation must hit time-to-therapy targets in a region before national rollout. [12, 13]
Accelerate means accelerate outcomes, not accelerate spend.
4
Transform gate — B·E·A production stability
Before any agentic AI deployment, confirm all three prior tiers are production-stable. Live claims feeds with documented SLA, mastered identity with ≥85% match rate, and closed-loop signal architecture returning outcomes. [15, 8]
AT the frontier only after BEA are earned.
5
The continuous loop
Once all four tiers are active, Transform surfaces gaps that Build must fix. Enable retrains on new signal. Accelerate adjusts strategy. The sequence becomes a loop — BEAT feeds itself. [17, 19]
The Most Common Sequencing Mistakes
Investing at the tier you wish you were in
Approving NBA vendor contracts before MDM exists. Announcing Transform strategy before Accelerate has proven lift. Budget follows ambition, not maturity. The result: 60% of AI projects lacking AI-ready data are abandoned before delivery. [1]
Treating Build as solved after initial deployment
CRM deployed = Build complete. Wrong. CRM data degrades materially without active governance — 74% of healthcare staff report duplicated efforts due to siloed data. [23] Every AI model above inherits the rot. [6, 8]
Setting Transform timelines before gates are passed
Board approves agentic AI roadmap for Year 1. Build is not stable. Enable is not mastered. The agent deploys into an environment it can’t trust. Credibility cost outlasts technology cost by years. [15]
Using launch date as the Accelerate gate
NBA goes live on day one of launch because that was the plan. MDM match rate is 64%. The AI recommends the wrong HCPs, at the wrong accounts, with the wrong message. Field loses confidence in 60 days. [23, 1]
Three Questions for Every Investment Decision
1. Which B·E·A·T tier does this investment belong to — and is that tier’s gate already passed?
2. Which of the four stakeholders (HCP, patient, field team, payer) does this directly serve — and how?
3. What commercial metric does this move, and by when? If you can’t answer this, it belongs in the backlog — not the roadmap.
Interactive Decision Tool

Score your organization.
See your B·E·A·T posture instantly.

Drag each slider to score 1–3. Your total maps to one of four investment quadrants — with specific sequence, watchouts, and AI readiness guidance.

B·E·A·T Criteria
12 /18
Org scale2
Portfolio breadth and resourcing capacity
1 · Small3 · Large
Speed pressure2
Launch window or competitive urgency
1 · Urgent3 · Low urgency
Tech maturity2
CRM, claims, MDM stability today
1 · Low3 · High
Capital runway2
Budget and brand lifecycle stage
1 · Tight3 · Full
Change capacity2
Field and ops adoption bandwidth
1 · Low3 · High
Compliance burden2
GxP, HIPAA, MLR (Medical-Legal-Regulatory) cycle speed
1 · Heavy3 · Light
AI Investment Appetite
AI ambition level2
Where is leadership currently pushing to invest?
1 · Foundation (B/E)3 · Transform
Investment Posture Matrix
↑ High Maturity
Technology
Maturity
Q1 · BUILD DEEP
All tiers · Transform focus
Low Urgency · High Maturity
Q2 · ACCELERATE NOW
Parallel B+E · Fast A
High Urgency · High Maturity
Q3 · BUILD FIRST
Sequential only · No skip
Low Urgency · Low Maturity
Q4 · TRIAGE & COMPRESS
MVP B · Accept risk
High Urgency · Low Maturity
Low Urgency
High Urgency →
Low
Move sliders to see your posture
Adjust the sliders → your B·E·A·T posture appears here
Apply B·E·A·T to Your Organization

The sequence is structural.
Every tier carries the weight of what sits above it.

Use the Decision Tool above to find your quadrant. Start with your gates. Build the tier you are actually in — not the one you wish you were in.

Application & Scope

Built in pharma.
Applicable everywhere.

The B·E·A·T Framework was forged in pharmaceutical commercial technology — one of the most complex, regulated, and data-intensive commercial environments in the world. But the sequencing problem it solves is not unique to pharma. Anywhere AI is deployed on top of fragmented data, the same failure pattern emerges.

Within Pharma Technology
Commercial Technology
CRM · Hub enrollment · HCP identity · NBA engines · Patient services · PA automation · Omnichannel engagement
Where B·E·A·T was developed and battle-tested
Medical Affairs Technology
Medical Liaison platforms · KOL identity · Evidence dissemination · Scientific exchange tracking · Outcomes Liaison analytics
Same sequence: identity before engagement, engagement before AI
Market Access & Payer Tech
Payer master data · Formulary tracking · Contract analytics · Real-world evidence · Value demonstration platforms
Fragmented payer identity = broken access strategy
R&D & Clinical Technology
Clinical trial data · Site master data · Patient registries · Regulatory submissions · Pharmacovigilance systems
Data integrity is patient safety. Build first, always.
Supply Chain & Manufacturing
Serialization · Cold chain tracking · Demand forecasting · Plant-level ERP integration · Quality systems
Operational reliability (Build) before predictive optimization
Beyond Pharma — The Same Pattern Everywhere
Financial Services
Client identity fragmented across wealth, retail, and institutional desks. AI personalization deployed before a golden client record exists. The model routes recommendations to the wrong account.
B·E·A·T fix: Client MDM before AI advisor
Healthcare Systems & Payers
Patient records fragmented across EHRs, claims, and care management. Predictive readmission models trained on incomplete data. Clinical AI makes confident wrong recommendations.
B·E·A·T fix: Patient identity before clinical AI
Retail & Consumer Goods
Customer data siloed across e-commerce, in-store, loyalty, and wholesale. Personalization engine recommends products the customer already returned. Same sequencing failure. Different industry.
B·E·A·T fix: Unified customer identity before NBA
MedTech & Industrial
Device serial numbers not reliably linked to accounts, service records, or patient outcomes. Predictive maintenance models trained on fragmented asset data. AI predicts failure — in the wrong device.
B·E·A·T fix: Asset master before predictive ops
The Universal Pattern
AI fails not because the model is wrong. It fails because the data underneath it was never ready to carry the weight.

This is the sequencing problem. Every organization that has deployed AI on top of fragmented identity, disconnected systems, or unmastered data has paid the same credibility cost. B·E·A·T names the pattern, gates the tiers, and gives technology leaders a decision framework that works regardless of therapeutic area, business unit, or industry vertical.

Intellectual Property & Copyright

The B·E·A·T Framework — including its sequencing model, tier definitions, gate system, decision tool, use case methodology, and all associated original content — is the intellectual property of Saurav Gupta. © 2026 Saurav Gupta. All rights reserved.

Permitted Use

Non-commercial professional discussion and citation with attribution is permitted. Commercial use, reproduction, training of AI systems on this framework, or adaptation without written permission is prohibited. Framework is applicable across industries and technology functions — original authorship must be preserved in any application or reference.

Citations & Sources

34 Verified References

All statistics and research claims in this framework are grounded in the following publicly available sources. Every reference was verified and confirmed findable as of April 2026. Numbers in brackets throughout the document correspond to these references.

Note on sourcing: This framework draws on research across Gartner, McKinsey, IQVIA, Accenture, URAC, Pharmaceutical Commerce, Optum, and industry publications. Sources include major consulting research, government and standards body reports, peer-reviewed case studies, and verified industry publications. All URLs were confirmed active at time of publication.
[1]
Gartner (2025)
“Lack of AI-Ready Data Puts AI Projects at Risk”
Gartner predicts 60% of AI projects lacking AI-ready data will be abandoned by 2026. Survey of 248 data management leaders, Q3 2024.
https://www.gartner.com/en/newsroom/press-releases/2025-02-26-lack-of-ai-ready-data-puts-ai-projects-at-risk
[2]
Gartner (2024)
“Gartner Predicts 30% of Generative AI Projects Will Be Abandoned After Proof of Concept By End of 2025”
At least 30% of GenAI projects abandoned after proof of concept due to poor data quality, inadequate risk controls, or unclear business value.
https://www.gartner.com/en/newsroom/press-releases/2024-07-29-gartner-predicts-30-percent-of-generative-ai-projects-will-be-abandoned-after-proof-of-concept-by-end-of-2025
[3]
McKinsey & Company (2023)
“The State of AI in 2023: Generative AI’s Breakout Year”
Pharma and medical products among highest-impact gen AI industries — potential value up to 5% of global industry revenue. Survey of 1,684 participants, April 2023.
https://www.mckinsey.com/capabilities/quantumblack/our-insights/the-state-of-ai-in-2023-generative-ais-breakout-year
[4]
McKinsey & Company (2023)
“The Economic Potential of Generative AI: The Next Productivity Frontier”
Gen AI expected to deliver 3–5% productivity value of global pharma/medical products revenue. Four functions account for 75% of total annual value.
https://www.mckinsey.com/capabilities/mckinsey-digital/our-insights/the-economic-potential-of-generative-ai-the-next-productivity-frontier
[5]
McKinsey & Company (2022)
“Demystifying the Omnichannel Commercial Model for Pharma Companies in Asia”
Well-executed omnichannel commercial transformation creates 5–10% revenue uplift, 10–20% marketing efficiency gains, 3–5% increase in prescribers.
https://www.mckinsey.com/jp/en/our-insights/demystifying-the-omnichannel-commercial-model-for-pharma-companies-in-asia
[6]
McKinsey & Company (2023)
“How Medtechs Can Meet Industry Demand for Omnichannel Engagement”
Companies with the highest omnichannel maturity had more than 2× the revenue growth of average maturity peers (2021–2022). Survey of 1,900+ medtech leaders.
https://www.mckinsey.com/industries/life-sciences/our-insights/how-medtechs-can-meet-industry-demand-for-omnichannel-engagement
[7]
IQVIA Institute for Human Data Science (2023)
“The Global Use of Medicines 2023: Outlook to 2027”
Global pharmaceutical market forecast to reach ~$1.9 trillion by 2027. Annual report on global medicine spending and usage trends.
https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2023
[8]
IQVIA (2023)
“AI in Life Sciences Commercialization”
Survey of commercial leaders on AI adoption patterns, data readiness, and commercial AI deployment barriers in life sciences.
https://www.iqvia.com/library/white-papers/ai-in-life-sciences-commercialization
[9]
Accenture (2023)
“Biopharma Technology Trends 2023”
Nearly 40% of life sciences work hours will be impacted by AI — augmented or automated. Four tech trends reshaping biopharma commercialization.
https://www.accenture.com/us-en/insights/life-sciences/biopharma-technology-trends-2023
[10]
Accenture Life Sciences (2023)
“Reinventing Commercialization: Shaping a More Modern & Sustainable Model”
Five-year study of 15 biopharma companies: top 8 performers averaged $1B extra annual revenue vs. analyst forecast (2018–2022). Via Fierce Pharma.
https://www.fiercepharma.com/pharma/investment-and-innovation-are-critical-maximizing-commercial-performance-report
[11]
McKinsey & Company (2022)
“AI Ushers In Next-Gen Prior Authorization in Healthcare”
Physicians spend an average of 13 hours/week on PA-related processes. 93% report care delays; 88% report high administrative burden.
https://www.mckinsey.com/industries/healthcare/our-insights/ai-ushers-in-next-gen-prior-authorization-in-healthcare
[12]
URAC (2023)
“2022 Specialty Pharmacy Performance Measurement: Aggregate Summary Report”
Average total time to fill specialty pharmacy prescriptions: 5.78 business days. New prescriptions take ~3× longer than refills. Based on 343 specialty pharmacies.
https://www.urac.org/wp-content/uploads/2023/02/2022_URAC_Specialty-Pharmacy_Aggregate-Summary-Report.pdf
[13]
VMS BioMarketing / MM+M (2024)
“Hub Services, Patient Engagement, and Specialty Pharmacy: One Patient Support Ecosystem”
Case study: patient engagement provider reduced hub receipt-to-dispense time from 18-day historical average to 9.8 days. 15%+ improvement in 90-day persistence rate.
https://www.mmm-online.com/home/channel/sponsored/vms-biomarketing-one-patient-support-ecosystem/
[14]
Pharmaceutical Commerce (2023)
“Next Best Action for Data Analytics”
Pharma manufacturer spending on data analytics forecast to grow 27% CAGR, reaching $1.2B by 2030. NBA systems represent a new era of data science in drug commercialization.
https://www.pharmaceuticalcommerce.com/view/-next-best-action-for-data-analytics
[15]
IQVIA (2023)
“Mastering the Art of Next Best Action: A Beginner’s Guide for the Pharmaceutical Industry”
Over 80% of pharmaceutical companies expected to implement or have a Next Best Action (NBA) program by end of 2023.
https://www.iqvia.com/locations/united-states/blogs/2023/04/mastering-the-art-of-next-best-action
[16]
Naviant (WPS Health Solutions case study) (2023)
“How AI Technology Reduces Prior Authorization Processing Time by 30.27%”
Real-world deployment: AI-powered PA system achieved 30.27% reduction in PA processing time, handling 170,000 documents annually.
https://naviant.com/blog/ai-prior-authorizations/
[17]
Grand View Research (citing Cardinal Health, 2022) (2024)
“Pharma Hub and Patient Access Support Service Market Report 2033”
More than 90% of physicians face patient care delays due to prior authorization; 37% abandon PA requests entirely.
https://www.grandviewresearch.com/industry-analysis/pharma-hub-patient-access-support-service-market-report
[18]
Optum Rx (2024)
“Automating the Prior Authorization Process”
Cleveland Clinic pilot: 88% reduction in PA appeals, 68% reduction in denials due to missing information. Physician abandonment rate fell from 31% to 25%.
https://business.optum.com/en/insights/automating-prior-authorization-process.html
[19]
McKinsey & Company (2025)
“The State of AI: How Organizations Are Rewiring to Capture Value”
78% of organizations now use AI in at least one business function; only ~1% of executives describe gen AI rollouts as ‘mature.’ Scaling gap remains defining challenge.
https://www.mckinsey.com/capabilities/quantumblack/our-insights/the-state-of-ai-how-organizations-are-rewiring-to-capture-value
[20]
Phil.us (2023)
“Hubs, Digital Pharmacies, and Specialty Pharmacies: What Pharma Access Teams Should Know”
Specialty drugs accounted for 55% of net pharmaceutical spending in 2022 (up from 28% in 2011). An estimated 3 out of 4 patients fail to fill a new specialty brand prescription due to payer controls.
https://phil.us/hubs-digital-pharmacies-and-specialty-pharmacies-what-pharma-access-teams/
[21]
Pharmaceutical Executive (2023)
“22nd Annual Industry Audit: The Pharma Value Picture”
The average SG&A-to-sales ratio for top pharma companies in 2022 was 40.5%. Large pharma companies routinely spend 25–40% of revenue on SG&A, which includes all commercial operations and technology investment.
https://www.pharmexec.com/view/22nd-annual-industry-audit-pharma-value-picture
[22]
SS&C Blue Prism (2023)
“Intelligent Automation for Provider Prior Authorization”
Healthcare providers implementing authorization automation reduce processing times for high-risk authorizations from 8–10 days to 4–5 days. With fully automated solutions, processing targets of 24–48 hours become achievable.
https://www.blueprism.com/resources/blog/healthcare-prior-authorization-automation/
[23]
Pharmaceutical Executive (2025)
“Pharma’s Next Commercial Frontier: Orchestrating Data, AI, and CRM for True Customer Centricity”
In one global program, consolidating 12 regional CRMs into a single engagement graph reduced duplicate HCP records by nearly half and improved launch readiness by more than 25%. Teams aligned on a unified HCP identity achieved real-time field productivity visibility. Also cites: 74% of healthcare staff report duplicated efforts due to siloed data sources (BMC Health Services Research).
https://www.pharmexec.com/view/next-commercial-frontier-orchestrating-data-ai-crm-true-customer-centricity
[24]
Veeva Systems (2024)
“The State of Data, Analytics, and AI in Commercial Biopharma”
Survey of 116 senior life sciences leaders. 89% of biopharma AI pilots fail to scale. 96% of leaders say their data is not AI-ready for fully scaling pilots. 67% have abandoned an AI initiative due to bad data foundation. 73% report significant data quality issues. 72% of companies spend up to 100 days/year reconciling HCP data. Fragmented data linked to 2-month launch delays and 15% lower early script volume in documented case study.
https://www.veeva.com/resources/the-state-of-data-analytics-and-ai-in-commercial-biopharma/
[25]
BCG (Boston Consulting Group) (2023)
“Scaling AI Pays Off, No Matter the Investment”
Based on BCG’s Digital Acceleration Index survey of 2,700 business leaders across 21 countries. Only 11% of companies have released significant value from AI; the majority have failed to scale AI beyond pilots. AI leaders invest an average of 4% of revenues in AI-specific initiatives vs. 2.7% for laggards.
https://www.bcg.com/publications/2023/scaling-ai-pays-off
[26]
BCG (Boston Consulting Group) (2022)
“Mind the Tech Gap” — BCG Digital Transformation Survey
Survey of nearly 2,700 executives across 13 countries. 94% of companies want substantial digital transformation impact, but 70% of digital transformations fail to achieve their objectives, often with profoundly damaging consequences. 60% plan to increase digital spending despite economic headwinds.
https://www.bcg.com/press/1december2022-bcg-x-new-hybrid-of-consulting-and-tech-build-design-capabilities
[27]
BCG (Boston Consulting Group) (2020)
“Flipping the Odds of Digital Transformation Success”
Only 30% of digital transformations succeed in achieving their objectives and creating sustainable change. The 44% in the “worry zone” create some value but miss targets. The 26% in the “woe zone” create less than 50% of target value. Successful transformations created 66% more value and improved corporate capabilities by 82% vs. failures.
https://www.bcg.com/publications/2020/increasing-odds-of-success-in-digital-transformation
[28]
ZS Associates — ZAIDYN® Orchestration Engine (2024)
“NBA-Driven Customer Engagement with ZAIDYN Orchestration Engine”
ZS’s ZAIDYN platform drives personalization at scale, leading to a 15–40% increase in customer engagement through omnichannel Next Best Action. The platform integrates CRM, MDM, claims, and digital data into a unified decisioning engine. Requires a clean, mastered HCP identity layer as the foundation; fragmented identity data produces recommendations field teams cannot trust.
https://www.zs.com/insights/omnichannel-nba-personalization-zaidyn-orchestration-engine
[29]
Databricks (2024)
“Elevating Customer Experience with AI-Enabled Omnichannel Next Best Action”
AI-enabled omnichannel NBA improves HCP engagement by 30–40% and increases sales by 4–10%. Requires data integration across customer profiles, sales data, and engagement history. An HCP receives an average of nine solicitations daily; NBA’s impact depends entirely on data quality and identity resolution underpinning the recommendation engine.
https://www.databricks.com/blog/elevating-customer-experience-ai-enabled-omnichannel-next-best-action
[30]
ZS Associates — Life Sciences Customer Engagement (2025)
“What Every Life Sciences Leader Needs to Know About Customer Engagement in 2025”
SG&A expenses in life sciences range from 25–40% of revenue; marketing and sales make up about 85% of that. Pharma is preparing for 400+ new product launches over the next five years. Among top-20 pharma companies, “digital pioneers” who built centralized data infrastructure first have achieved the highest omnichannel maturity. The key barrier to true omnichannel: no single owner of the customer identity. Without a central, unified HCP view, commercial teams remain fragmented.
https://www.zs.com/insights/life-sciences-leaders-customer-engagement-2025
[31]
Salesforce (2024)
“Salesforce Life Sciences Cloud & Unified Data Platform for Life Sciences”
Life Sciences Cloud uses a Unified Data Platform (Data Cloud + MuleSoft) to create harmonized HCP and patient profiles from CRM, claims, prescriptions, EHRs, and engagement history. The platform illustrates the Enable tier’s architecture: unified identity, consent, and cross-channel signal are prerequisites before AI-driven next best action and agentic engagement can function. 88% of healthcare and life sciences organizations have not yet realized their digital transformation goals. Pharma companies using unified CRM data report reduced redundant outreach and improved AI-powered recommendations.
https://www.salesforce.com/news/stories/life-sciences-cloud-ai-availability/
[32]
EY (Ernst & Young) (2023)
“How Electronic Prior Authorization Can Help Health Care”
EY research documents that reducing administrative overhead and improving payer-provider collaboration via PA automation requires an end-to-end approach with digital workflows and real-time EHR connectivity. Current PA processes take up valuable time and resources that could otherwise be used to save costs and provide patients more timely care. A next-generation PA experience requires rapid shifts in organizational priorities, a digital operating model, and advanced technology capabilities — none of which function without integrated claims data and unified patient identity as the foundation.
https://www.ey.com/en_us/insights/health/how-electronic-prior-authorization-can-help-health-care
[33]
CoverMyMeds / McKesson (2023)
“Benefits of Outsourcing Field Reimbursement Services” & Patient Support Program Data
PA delays range from days to weeks without automation. CoverMyMeds e-enrollment reduces time to therapy by up to 4 days (study across 3 drugs, 33,000+ enrollments over 2 years). When Reimbursement Specialists are deployed with hub technology integration, hub programs see an average 8% increase in patient enrollment following a PA denial. Siloed hub and patient support services mean field teams often lack visibility into patient journey data — the exact problem the Build tier is designed to solve. PA and benefit verification are “table stakes” for the specialty patient support field.
https://insights.covermymeds.com/healthcare-industry/pharma/benefits-of-outsourcing-field-reimbursement-services-with-covermymeds
[34]
MIT Sloan Management Review (2023)
“Why AI Projects Fail” — AI Success Factors in Enterprise
MIT Sloan research on enterprise AI deployments confirms that AI success depends on data maturity and process integration, not model sophistication. Organizations that invest in data infrastructure and cross-functional process alignment before deploying AI models achieve materially better outcomes. Agentic and autonomous AI capabilities in particular require production-stable data foundations — otherwise automation amplifies existing errors at scale rather than reducing them. The technology is rarely the limiting factor; the data and process architecture underneath it is.
https://sloanreview.mit.edu/article/why-ai-projects-fail/
SG
Saurav Gupta — Personal Perspective & Disclaimer
The views expressed in this framework are those of Saurav Gupta personally and do not represent the views, positions, strategies, or endorsement of any employer, client, or affiliated organization. The B·E·A·T Framework is original practitioner work based on industry experience and publicly available research. Customer personas are illustrative composites. © 2026 Saurav Gupta. Reproduction permitted with attribution for non-commercial professional discussion.
The B·E·A·T Framework · Saurav Gupta · 2026
Top Framework Decision Tool References
Personal views of Saurav Gupta — not representative of any employer or client. © 2026